Shaping a future free from Alzheimer's disease
Maria Mora Pinzon, MD, MS, FACPM, recently appeared on Telemundo Wisconsin in a news segment discussing FDA approval of the drug lecanemab. The drug gained approval through an accelerated approval process in January 2023. Dr. Mora Pinzon is assistant professor at University of Wisconsin School of Medicine and Public Health and a scientist with the …
On behalf of the Initiative to End Alzheimer’s, we are pleased to announce the IEA Innovation Fund, providing project support for researchers at Wisconsin Alzheimer’s Institute and Wisconsin Alzheimer’s Disease Research Center. The fund was launched in March 2023, with initial support of $100,000 to be awarded on a rolling basis. The IEA Innovation Fund …
UW Alzheimer's disease researchers Dr. Carlsson, Dr. Johnson and Dr. Chin discuss Alzheimer's drug lecanemab in video episode of Dementia Matters podcast.
Coffee and a Chat, a free, virtual event series. Join in from home – by computer or phone – and listen to health experts and ask questions.
First-year medical students are invited to apply today.
Dr. Mora Pinzon's work focuses on health services research in dementia care, and improving access to dementia care for Latinx individuals.
On a recent episode of the Dementia Matters podcast, host Nathaniel Chin, MD, gives an overview of the new Alzheimer’s treatment Leqembi (lecanemab), and highlights results from the second and third phases of its clinical trials.
Cynthia Carlsson, MD, MS, was recently interviewed by CBS 58 News in Milwaukee about the U.S. Food and Drug Administration (FDA) approval of Leqembi (lecanemab), which showed a reduction of clinical decline in a study of people with early Alzheimer’s disease. “What was impressive about this study is that it improved the amyloid levels in …
On January 6, the U.S. Food and Drug Administration (FDA) approved Leqembi (lecanemab-irmb) via the Accelerated Approval pathway for the treatment of Alzheimer’s disease. Leqembi is the second of a new category of medications approved for Alzheimer’s disease that target the fundamental pathophysiology of the disease. These medications represent an important advancement in the ongoing …
How sweet the sound at a live, in person concert on December 17.